3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Breast Neoplasms
5
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Breast Diseases
1
Interventions
Bevacizumab
39
Paclitaxel
35
pembrolizumab
27
Carboplatin
27
Specimen Handling
21
olaparib
19
Magnetic Resonance Spectroscopy
19
Gemcitabine
19
liposomal doxorubicin
17
Cyclophosphamide
16
niraparib
13
fludarabine
12
Topotecan
12
Cisplatin
12
Biopsy
12
Taxes
9
Nivolumab
8
Immunoglobulin G
8
Fulvestrant
8
Doxorubicin
8
Disulfides
8
Surveys and Questionnaires
7
palbociclib
6
aldesleukin
6
Oxaliplatin
6
Letrozole
5
Fluorouracil
5
trastuzumab deruxtecan
4
oregovomab
4
mirvetuximab soravtansine
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ovarian Neoplasms
×
Imlunestrant
×
90 days
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled